However, in AML bone marrow context, AML-derived MSCs express no significant change in CXCL12 (Geyh et al., 2016), but CXCR4, the receptor of CXCL12, is overactivated by AML cells (Zeng et al., 2009). This evidence concerns the gene CXCR4 and acute myeloid leukemia.